Silexion Therapeutics (SLXN) Accumulated Expenses (2023 - 2026)

Silexion Therapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $560000.0 for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 10.26% year-over-year to $560000.0; the TTM figure through Mar 2026 stood at $560000.0 (down 10.26% YoY), while the FY2025 annual figure was $879000.0, up 11.55% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $560000.0, down from $879000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $1.9 million in Q3 2024, with the low at $560000.0 in Q1 2026.
• The 4-year median for Accumulated Expenses is $879000.0 (2025), against an average of $1.0 million.
• Peak annual rise in Accumulated Expenses reached 11.55% in 2025, while the deepest fall reached 54.46% in 2025.
• Silexion Therapeutics' Accumulated Expenses stood at $1.4 million in 2023, then plunged by 41.97% to $788000.0 in 2024, then advanced by 11.55% to $879000.0 in 2025, then sank by 36.29% to $560000.0 in 2026.
• Business Quant data shows SLXN's Accumulated Expenses at $560000.0 in Q1 2026, $879000.0 in Q4 2025, and $945000.0 in Q3 2025.